List view / Grid view
29 October 2015 | By Victoria White
The global multiple myeloma treatment market will rise in value from $8.9 billion in 2014 to an estimated $22.4 billion by 2023, according to research and consulting firm GlobalData...
29 October 2015 | By Victoria White
Allergan has said that it is in preliminary “friendly discussions” with Pfizer regarding a potential business combination transaction...
29 October 2015 | By Victoria White
This approval is based on clinical data from a pivotal Phase 3 trial which demonstrated Yervoy significantly improved recurrence-free survival vs. placebo in this setting...
29 October 2015 | By Victoria White
The trial is a milestone in cancer treatment as the first to show the benefits of ‘precision medicine’ in prostate cancer...
29 October 2015 | By Victoria White
To mark its support for World Stroke Day, Daiichi Sankyo has initiated a campaign that highlights stroke risks associated with cardiovascular diseases...
28 October 2015 | By Victoria White
Tolavptan is the first-ever treatment shown to slow progression of the life-threatening condition...
28 October 2015 | By Victoria White
Boehringer Ingelheim today announced new data from post-hoc analyses of studies of Spiolto Respimat and a Phase I trial of its adalimumab biosimilar candidate...
28 October 2015 | By Victoria White
Gilteritinib has demonstrated inhibitory activity against FLT3 internal tandem duplication as well as tyrosine kinase domain, two common types of FLT3 mutations that are seen in AML...
28 October 2015 | By Kate Douetil
GSK’s candidate shingles vaccine is a non-live vaccine and combines gE, a protein found on the virus that causes shingles with an adjuvant system, AS01B, which enhances the immunological response to gE...
28 October 2015 | By Victoria White
Imylgic is a genetically modified herpes simplex virus type 1 designed to replicate within tumours and produce an immunostimulatory protein called GM-CSF...
28 October 2015 | By Victoria White
New clinical data indicate no differences in efficacy, adverse events and immunogenicity when patients with inflammatory bowel disease are switched to biosimilar infliximab Remsima from originator infliximab...
27 October 2015 | By Victoria White
Data from a Phase 1 trial evaluating Adcetris plus AVD demonstrated that 24 of 25 patients (96 percent) achieved a complete remission...
27 October 2015 | By Victoria White
Withdrawing donepezil from people in the advanced stages of Alzheimer's disease doubles their risk of being placed in a nursing home within a year, according to a UCL study...
27 October 2015 | By Victoria White
An interim review of data from part A of the Phase III study did not indicate efficacy against the primary endpoint and did not support investment in the larger part B of the study...
27 October 2015 | By Victoria White
The start-up of this study resulted in $62.5M of milestone payments to Merrimack from Baxalta...
